Intermedine

Calcitonin Peptide FamilyRx: ResearchCompound: Research

Also known as: ADM2, Adrenomedullin 2, Intermedin, Melanocyte-stimulating hormone (intermediate lobe), Pars intermedia MSH, β-MSH (in some species)

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Intermedine at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Intermedine (also known as adrenomedullin‑2 or intermedin) is a 53‑amino‑acid endogenous peptide of the calcitonin family that acts as a vasodilator and has cardioprotective and metabolic effects in pre‑clinical studies.

Mechanism of Action

Activates the calcitonin receptor-like receptor (CLR) complexed with RAMP2 or RAMP3, increasing intracellular cAMP and causing vasodilation and cardioprotective signaling

Routes of Administration

IntraperitonealIntravenousSubcutaneous

Goals & Uses

  • Heart failure treatmentCardiovascularLow
  • Energy homeostasis / Feeding behaviorMetabolicLow
  • Metabolic regulationEndocrineLow
  • Melanogenesis / Skin PigmentationPigmentationModerate
  • Cardiovascular modulationCardiovascularLow
  • Anti-inflammatory effectsInflammationLow
  • VasodilationCardiovascular SupportModerate

Contraindications

  • Known hypersensitivity to melanocortin peptidesAllergy/ImmunologyHigh
  • Melanoma or pigmented lesion historyOncologyHigh

Adverse Effects

  • Injection site reactionsLocalUnknown
  • HeadacheNeurologicUnknownPain in the head or upper neck
  • HypotensionCardiovascularUnknownLow blood pressure
  • Cardiovascular effects (blood pressure changes)CardiovascularUnknown
  • NauseaGastrointestinalUnknownFeeling of sickness or urge to vomit
  • HyperpigmentationDermatologicUnknown

Drug Interactions

  • Other melanocortin receptor agonists/antagonistsModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Patients with active malignancyOncologyRelative
  • Pediatric populationsAgeRelative

Regulatory Status

  • European UnionUnapprovedNo EMA approval
  • United StatesUnapprovedNo FDA approval
  • United KingdomUnapprovedNo MHRA approval

Not approved for any therapeutic indication; used only in experimental and pre‑clinical settings.

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is Intermedine?

Intermedine (also known as adrenomedullin‑2 or intermedin) is a 53‑amino‑acid endogenous peptide of the calcitonin family that acts as a vasodilator and has cardioprotective and metabolic effects in pre‑clinical studies.

What is Intermedine used for?

Intermedine is educationally associated with: Heart failure treatment, Energy homeostasis / Feeding behavior, Metabolic regulation, Melanogenesis / Skin Pigmentation, Cardiovascular modulation, Anti-inflammatory effects, Vasodilation. Educational only — not medical advice.

How is Intermedine administered?

Recorded routes of administration: Intraperitoneal, Intravenous, Subcutaneous.

What are the potential side effects of Intermedine?

Reported adverse effects include: Injection site reactions, Headache, Hypotension, Cardiovascular effects (blood pressure changes), Nausea, Hyperpigmentation. This list is not exhaustive — consult a qualified clinician.

Who should avoid Intermedine?

Recorded contraindications: Known hypersensitivity to melanocortin peptides, Melanoma or pigmented lesion history. Consult a qualified clinician before use.